Together, these findings are supported by other studies in the literature, where it has been shown that abrogation of one or more of the four genes (survivin, Mcl-1, XIAP and cIAP2) would inhibit tumor growth, sensitize drug resistant cancer cells to treatment and induce apoptosis in various in vitro and in vivo models [59]–[67]. The gene discussed is BIRC5; the disease is neoplasm.